RBP-01 not checked

ReBio Pharma

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Each RBP-01 dose consists of a 5 µL intravitreal injection conjugating 250 µg of sotrastaurin.”In the company’s words, NCT07747935 on ClinicalTrials.gov
Tested for
Uveal Melanoma
Main trialPhase 1/2
“Neoadjuvant RBP-01 in patients with primary uveal melanoma.”In the company’s words, NCT07747935 on ClinicalTrials.gov

Other drugs for Uveal Melanoma

All 20 drugs for Uveal Melanoma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting 1 Apr 2028 Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RBP-01

Following is part of Solo: you see every change to RBP-01 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in